Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
The most common adverse reactions in patients taking Xofluza included diarrhea and bronchitis.
For more information, please visit: Xofluza.
No hay comentarios:
Publicar un comentario